Related references
Note: Only part of the references are listed.Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition
Alastair I. Bartlett et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi et al.
CLINICAL CANCER RESEARCH (2011)
Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed
Timothy D'Alfonso et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer
Julie M. Wu et al.
HUMAN PATHOLOGY (2010)
Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer
Rebecca A. Burrell et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype
So Yeon Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Matteo Brunelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
HER-2/neu expression in primary and metastatic breast cancer
Elyse E. Lower et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The equivocally amplified HER2 FISH result on breast core biopsy -: Indications for further sampling do affect patient management
Joan M. Striebel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
Yolanda Madarnas et al.
CANCER TREATMENT REVIEWS (2008)
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
C. L. Hyun et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer
P. H. Cottu et al.
ANNALS OF ONCOLOGY (2008)
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American society of clinical Oncology/College of American pathologists guidelines:: tumor heterogeneity in breast cancer and its implications for tissue Microarray based assessment of outcome
Christopher B. Moeder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
Laurent Arnould et al.
CLINICAL CANCER RESEARCH (2007)
Intratumoral heterogeneity of HER2/neu in breast cancer -: A rare event
Wedad Hanna et al.
BREAST JOURNAL (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer as an evolutionary and ecological process
Lauren M. F. Merlo et al.
NATURE REVIEWS CANCER (2006)
Intratumoral heterogeneity of HER-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray
Sandra J. Shin et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2006)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Scott L. Carter et al.
NATURE GENETICS (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
JT Lewis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice
Y Ma et al.
CLINICAL CANCER RESEARCH (2005)
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Y Gong et al.
CANCER (2005)
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
P Regitnig et al.
JOURNAL OF PATHOLOGY (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Marked intratumoral heterogeneity of c-myc and CyclinD1 but not of c-erbB2 amplification in breast cancer
S Glöckner et al.
LABORATORY INVESTIGATION (2002)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
